Key points from article :
Nura Bio has raised an additional $68 million, bringing its Series A financing total to $140 million. The company focuses on developing neuroprotective therapies to address axon degeneration, a critical factor in many neurological disorders. Axon degeneration can compromise the nervous system's structure and function, and Nura Bio aims to prevent this through targeted therapies.
Their lead drug, NB-4746, is designed to inhibit SARM1, an enzyme responsible for triggering axonal destruction after injury. Preclinical studies have demonstrated that inhibiting SARM1 can protect axons and improve function in various nervous system diseases. A Phase 1 clinical trial in healthy volunteers showed that NB-4746 was well-tolerated, with no serious side effects, and effectively reached the brain with targeted plasma exposure.
With these encouraging results, Nura Bio plans to begin a Phase 1b/2 trial in patients by 2025. The company also explores ways to restore the body’s ability to clear damaged neurons, aiming to improve neuroimmune pathways and offer another layer of neuroprotection.
The additional funding, supported by new and existing investors, will help advance Nura Bio’s pipeline of therapies targeting neurodegenerative diseases. This financing enables further research and development, positioning the company to test their neuroprotective strategies in clinical settings, with the goal of addressing large unmet medical needs.
